Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article evaluates sexual function using the International Index of Erectile Function in people taking finasteride for androgenetic alopecia but does not present new findings.

More inflammation leads to faster and worse hair loss in women with frontal fibrosing alopecia.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

This case report identifies a novel maternally inherited MBTPS2 variant associated with an expanded phenotypic spectrum of BRESHECK syndrome, including cytopenias, bone marrow fibrosis, and chronic diarrhea.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

In this study, fibroblasts treated with the small molecule peficitinib were reprogrammed into dermal papilla cell-like cells capable of inducing hair growth, offering a new strategy for hair loss treatment.

This case report illustrates that fibrosing alopecia in a pattern distribution may be misdiagnosed as androgenetic alopecia due to similar hair loss patterns, but distinctive trichoscopic and histopathologic features help differentiate it.

This review discusses the potential applications of injectable platelet‐rich fibrin in various conditions and reports no new clinical results; the authors highlight its favorable use in comparison to existing treatments.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

In this case report, a woman initially misdiagnosed with rosacea was later correctly diagnosed with frontal fibrosing alopecia after further examination and treated with oral finasteride and hydroxychloroquine to stabilize her condition.

This review discusses risk factors for intraoperative floppy iris syndrome, emphasizing tamsulosin and other α1 blockers, and underscores the importance of preoperative screening to mitigate surgical complications, but it reports no new results.

This study constructed a hair follicle-specific expression vector for IGFBP-5 in Inner Mongolia Cashmere goat cells, allowing for future functional genetic analyses and potential use in nuclear transfer.

This study suggests that infrared thermography may be a useful noninvasive tool for diagnosing active phases of frontal fibrosing alopecia when combined with dermoscopy.

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

This study observed that oral tofacitinib was reasonably well-tolerated but had limited efficacy in treating alopecia areata, with a clinical response seen in 41.4% of patients over six months.

This study found that the novel IPC analog SIG-1451 may inhibit inflammatory cytokine release in cell-based assays relevant to allergic dermatitis.

In this study, Dodatek A operationalizes the Functional Androgen Axis framework by defining three system-level indices and an efficiency metric to describe androgen function, incorporating key methodological improvements and acknowledging significant limitations for future empirical validation.

This case report suggests that tofacitinib may effectively manage symptoms of AGS7 in a patient with an IFIH1 mutation, though further studies are needed to confirm its long-term safety and efficacy.

This study revealed that IP-PA1, derived from Pantoea agglomerans, promoted hair growth in mice and increased certain growth factor expressions in human cell cultures, suggesting a unique mechanism compared to traditional hair growth treatments.

This study found that the Arabidopsis thaliana protein Formin 2 localizes to plasmodesmata and is crucial for regulating their permeability by anchoring actin filaments, which affects virus susceptibility.

This study found that tofacitinib may be effective for treating pediatric rheumatic diseases, with especially promising results in patients with autoinflammatory diseases, arthritis and alopecia, and juvenile dermatomyositis.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This article introduces a new grading system called the FPHL Severity Index to better identify and monitor early stages of female pattern hair loss using clinical criteria.

This study demonstrated that the IVL-DrugFluidic® platform is effective for mass-producing finasteride-loaded polymeric microspheres for long-acting injectables, maintaining stable drug release without an initial burst for a month.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

In this study, freezing gamma-irradiated amniotic fluid increased hair follicles and accelerated the transition to the anagen stage in rats, suggesting potential for treating hair loss safely and effectively.